Prosecution Insights
Prosecution Insights
25 pending office actions • 19 clients • 25 examiners • 20 art units • 0 of 25 (0%) have an AI response strategy ready • 20 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 12 (48%) |
| §102 only | 2 (8%) |
| §112 only | 2 (8%) |
| Double-patenting only | 6 (24%) |
| No statute on record | 3 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.3% | +17.6% |
| BOESEN, AGNIESZKA | 1 | 68.3% | +21.8% |
| AEDER, SEAN E | 1 | 56.7% | +20.0% |
| KATAKAM, SUDHAKAR | 1 | 74.8% | +23.3% |
| ROGERS, ERIC JASON | 1 | 57.8% | +30.0% |
| LAU, JONATHAN S | 1 | 64.0% | -18.4% |
| WILLIAMS, EMMALEE RAE | 1 | 0.0% | +0.0% |
| POPA, ILEANA | 1 | 21.3% | +14.8% |
| SHIAO, REI TSANG | 1 | 79.8% | -34.0% |
| ALAM, DANYAL HASSAN | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18489420 | PRODUCTION OF TRICHODERMA SPP FUNGI USING ALMOND HULL AS A GROWTH MEDIUM | WILLIAMS, EMMALEE RAE | 12d |
| 18555385 | SIGNAL PEPTIDES | POPA, ILEANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | POLIAKOVA-GEORGAN, EKATERINA | 76d |
| 18667046 | RSV IMMUNIZATION REGIMEN | BOESEN, AGNIESZKA | — |
| 18688720 | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF | AEDER, SEAN E | — |
| 18570551 | GLUCAGON ANALOG AND MEDICAL USE THEREOF | KATAKAM, SUDHAKAR | — |
| 18564584 | RECOMBINANT ADENO-ASSOCIATED VIRUS HAVING VARIANT CAPSID, AND APPLICATION THEREOF | ROGERS, ERIC JASON | — |
| 18555385 | SIGNAL PEPTIDES | POPA, ILEANA | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1641 | 2 |
| 1647 | 2 |
| 1637 | 1 |
| 1658 | 1 |
| 1638 | 1 |
| 1653 | 1 |
| 1633 | 1 |
| 1691 | 1 |
| 1672 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19245022 | COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES | BASECURE THERAPEUTICS LLC | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103 | Final Rejection | 76d | Pending | Jun 20, 2025 |
| 18667046 | RSV IMMUNIZATION REGIMEN | Glaxosmithkline Biologicals SA | BOESEN, AGNIESZKA | DP | Non-Final OA | — | Pending | May 17, 2024 | |
| 18688720 | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF | Novarock Biotherapeutics, Ltd. | AEDER, SEAN E | DP | Non-Final OA | — | Pending | Mar 01, 2024 | |
| 18570551 | GLUCAGON ANALOG AND MEDICAL USE THEREOF | BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD. | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18564584 | RECOMBINANT ADENO-ASSOCIATED VIRUS HAVING VARIANT CAPSID, AND APPLICATION THEREOF | Shanghai Regenelead Therapies Co., Ltd. | ROGERS, ERIC JASON | 1638 | §103 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18564512 | QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS | Shanghai Hengrui Pharmaceutical Co., Ltd. | LAU, JONATHAN S | 1693 | §103 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18489420 | PRODUCTION OF TRICHODERMA SPP FUNGI USING ALMOND HULL AS A GROWTH MEDIUM | Select Harvests Limited | WILLIAMS, EMMALEE RAE | 1653 | Other | Non-Final OA | 12d | Pending | Oct 18, 2023 |
| 18555385 | SIGNAL PEPTIDES | Imperial College Innovations Limited | POPA, ILEANA | 1633 | §103 | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18286536 | BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITOR | Tuojie Biotech (Shanghai) Co., Ltd. | SHIAO, REI TSANG | 1691 | §103 | Final Rejection | — | Pending | Oct 11, 2023 |
| 18456354 | RETROVIRAL VECTORS | Ip2Ipo Innovations Limited | ALAM, DANYAL HASSAN | 1672 | DP | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18278373 | ANTIBODIES AGAINST CLAUDIN-6 AND USES THEREOF | Novarock Biotherapeutics, Ltd. | DIBRINO, MARIANNE | 1641 | Other | Non-Final OA | — | Pending | Aug 22, 2023 |
| 18274511 | PLASMA KALLIKREIN ANTIBODIES AND USES THEREOF | Astria Therapeutics, Inc. | CHHAY, BONIRATH | 1645 | DP | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18272336 | A PROCESS FOR RECOVERING COBALT FROM LITHIUM-ION BATTERIES | Newsouth Innovations Pty Ltd | PARK, LISA S | 1729 | §103 | Non-Final OA | 28d | Pending | Jul 13, 2023 |
| 18268104 | COMPLEX OF ANTI-IL-4R ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | Shanghai Shengdi Pharmaceutical Co., Ltd. | LANDSMAN, ROBERT S | 1647 | §103 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18265217 | MULTISPECIFIC ANTIGEN BINDING PROTEIN | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | HADDAD, MAHER M | 1641 | §102 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18298882 | COMBINATION TREATMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | SHIBUYA, MARK LANCE | 1631 | §103 | Non-Final OA | 15d | Pending | Apr 11, 2023 |
| 18024725 | A PROCESS FOR PREPARING FERTILIZER COMPOSITIONS | Select Harvests Limited | SILVA RAINBOW, HEATHER ELISE | 1731 | §103 | Non-Final OA | 9d overdue | Pending | Mar 03, 2023 |
| 18024631 | DERIVATISATION OF PEPTIDES AND PROTEINS | Florey Institute Of Neuroscience And Mental Health | CHANDRA, GYAN | 1674 | §102 | Non-Final OA | 141d overdue | Pending | Mar 03, 2023 |
| 18022091 | HYALURONIDASE FUSION PROTEINS COMPRISING A TARGETING SEQUENCE AND METHODS OF USING SAME TO TREAT A COSMETIC CONDITION | Standard Of Care Corporation | CURRENS, GRANT CARSON | 1651 | Other | Final Rejection | 18d overdue | Pending | Feb 17, 2023 |
| 18019763 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | Tuojie Biotech(Shanghai) Co., Ltd. | SHIN, DANA H | 1635 | §112 | Final Rejection | 75d | Pending | Feb 03, 2023 |
| 18013524 | ANTI-FXI/FXIA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF | BEIJING TUO JIE BIOPHARMACEUTICAL CO. LTD. | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | — | Pending | Dec 28, 2022 |
| 17913928 | PREPARATION METHOD FOR ANTIBODY MEDICAMENT CONJUGATE | Shanghai Hengrui Pharmaceutical Co., Ltd. | STONEBRAKER, ALYSSA RAE | 1642 | §103 | Final Rejection | — | Pending | Sep 23, 2022 |
| 17610440 | ANTIFUNGAL AGENTS FOR CANDIDA AURIS DECOLONIZATION | Scynexis, Inc. | GALSTER, SAMUEL LEONARD | 1693 | DP | Final Rejection | — | Pending | Nov 10, 2021 |
| 17399015 | ANTIFUNGAL AGENTS USED IN COMBINATION | Scynexis, Inc. | LEE, WILLIAM Y | 1623 | DP | Final Rejection | — | Pending | Aug 10, 2021 |
| 16971500 | METHODS OF PERFORMING CLINICAL TRIALS | Klaritos, Inc. | ERICKSON, BENNETT S | 3683 | §103 | Final Rejection | 38d overdue | Pending | Aug 20, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial